The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer
Open accessAbstract
Purpose: Belagenpumatucel-L is a nonviral gene-based allogeneic tumor cell vaccine that demonstrates enhancement of tumor antigen recognition as a result of transforming growth factor beta-2 inhibition. Patients and Methods: We performed a randomized, dose-variable, phase II trial involving stages II, IIIA, IIIB, and IV non–small-cell lung cancer patients. Each patient received one of three doses (1.25, 2.5, or 5.0 × 10 7 cells/injection) of belagenpumatucel-L on a monthly or every other month schedule to a maximum of 16 injections. Immune function, safety, and anticancer activity were monitored. Results: Seventy-five patients (two stage II, 12 stage IIIA, 15 stage IIIB, and 46 stage IV patients) received a total of 550 vaccinations. No significant adverse events were observed. A dose-related survival difference was demonstrated in patients who received ≥ 2.5 × 10 7 cells/injection (P = .0069). Focusing on the 61 late-stage (IIIB and IV) assessable patients, a 15% partial response rate was achieved. The estimated probabilities of surviving 1 and 2 years were 68% and 52%, respectively for the higher dose groups combined and 39% and 20%, respectively, for the low-dose group. Immune function was explored in the 61 advanced-stage (IIIB and IV) patients. Increased cytokine production (at week 12 compared with patients with progressive disease) was observed among clinical responders (interferon gamma, P = .006; interleukin [IL] -6, P = .004; IL-4, P = .007), who also displayed an elevated antibody-mediated response to vaccine HLAs (P = .014). Furthermore, positive enzyme-linked immunospot reactions to belagenpumatucel-L showed a correlation trend (P = .086) with clinical responsiveness in patients achieving stable disease or better. Conclusion: Belagenpumatucel-L is well tolerated, and the survival advantage justifies further phase III evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Chen, W., Jin, W., Hardegen, N., Lei, K.-J., Li, L., Marinos, N., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,699
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Non-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Shepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O’Rourke, M., Levitan, N., Gressot, L., Vincent, M., Burkes, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,181
Cancer burden in the year 2000. The global picture
Parkin, D. M., Bray, F. I., & Devesa, S. S. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00267-2 · Cited by 2,169
Interleukin-2: Inception, Impact, and Implications
Smith, K. A. (1988) · Science · doi:10.1126/science.3131876 · Cited by 2,153
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M.-S., Sakurada, A., Cutz, J.-C., Zhu, C.-Q., Kamel-Reid, S., Squire, J., Lorimer, I., Zhang, T., Liu, N., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,830
Nakamura, K., Kitani, A., & Strober, W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.5.629 · Cited by 1,594
Fossella, F. V., DeVore, R., Kerr, R. N., Crawford, J., Natale, R. R., Dunphy, F., Kalman, L., Miller, V., Lee, J. S., Moore, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2354 · Cited by 1,360
Tumor Antigens Recognized by T Lymphocytes
Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P., & Van Pel, A. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002005 · Cited by 1,221
Transforming Growth Factor-β: Biological Function and Chemical Structure
Sporn, M. B., Roberts, A. B., Wakefield, L. M., & Assoian, R. K. (1986) · Science · doi:10.1126/science.3487831 · Cited by 1,182
Fantini, M. C., Becker, C., Monteleone, G., Pallone, F., Galle, P. R., & Neurath, M. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5149 · Cited by 1,135
Woo, E. Y., Chu, C., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C., Kaiser, L. R., & June, C. H. (2001) · PubMed · Cited by 1,108
Transforming growth factor-beta in disease: the dark side of tissue repair.
Border, W. A., & Ruoslahti, E. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115821 · Cited by 1,105
Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB
Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K. H., & Spies, T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6879 · Cited by 1,028
Deactivation of macrophages by transforming growth factor-β
Tsunawaki, S., Sporn, M., Ding, A., & Nathan, C. (1988) · Nature · doi:10.1038/334260a0 · Cited by 861
Woo, E. Y., Yeh, H., Chu, C. S., Schlienger, K., Carroll, R. G., Riley, J. L., Kaiser, L. R., & June, C. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4272 · Cited by 696
Dendritic Cells in Cancer Immunotherapy
Fong, L., & Engleman, E. G. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.245 · Cited by 680
The TGF-β family of growth and differentiation factors
Massagué, J. (1987) · Cell · doi:10.1016/0092-8674(87)90443-0 · Cited by 664
Rook, A. H., Kehrl, J. H., Wakefield, L. M., Roberts, A. B., Sporn, M. B., Burlington, D. B., Lane, H. C., & Fauci, A. S. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.10.3916 · Cited by 570
Models of T cell anergy: is there a common molecular mechanism?
Schwartz, R. H. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.1.1 · Cited by 559
Mechanism of Transforming Growth Factor β–induced Inhibition of T Helper Type 1 Differentiation
Gorelik, L., Constant, S., & Flavell, R. A. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012076 · Cited by 521
Ranges, G. E., Figari, I. S., Espevik, T., & Palladino, M. A. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.4.991 · Cited by 494
Parkin, D. M., Bray, F. I., & Devesa, S. S. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00739-6 · Cited by 479
Bodmer, S., Strommer, K., Frei, K., Siepl, C., de Tribolet, N., Heid, I., & Fontana, A. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.10.3222 · Cited by 386
Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma
Enk, A. H., Jonuleit, H., Saloga, J., & Knop, J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971104)73:3<309::aid-ijc1>3.0.co;2-3 · Cited by 386
Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?
Grilli, R., Oxman, A. D., & Julian, J. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1866 · Cited by 382
Phenotype, Localization, and Mechanism of Suppression of CD4+CD25+ Human Thymocytes
Annunziato, F., Cosmi, L., Liotta, F., Lazzeri, E., Manetti, R., Vanini, V., Romagnani, P., Maggi, E., & Romagnani, S. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020110 · Cited by 379
Constam, D. B., Philipp, J., Malipiero, U. V., ten Dijke, P., Schachner, M., & Fontana, A. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.5.1404 · Cited by 373
Anergic T Cells as Suppressor Cells in Vitro
Lombardi, G., Sidhu, S., Batchelor, R., & Lechler, R. (1994) · Science · doi:10.1126/science.8202711 · Cited by 366
Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., Mercola, D., Black, K. L., Royston, I., & Sobol, R. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2909 · Cited by 334
Self-citationSoiffer, R., Hodi, F. S., Haluska, F., Jung, K., Gillessen, S., Singer, S., Tanabe, K., Duda, R., Mentzer, S., Jaklitsch, M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.005 · Cited by 305
Friese, M. A., Wischhusen, J., Wick, W., Weiler, M., Eisele, G., Steinle, A., & Weller, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1627 · Cited by 305
Salgia, R., Lynch, T., Skarin, A., Lucca, J., Lynch, C., Jung, K., Hodi, F. S., Jaklitsch, M., Mentzer, S., Swanson, S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.091 · Cited by 296
Nemunaitis, J., Sterman, D., Jablons, D., Smith, J. W., Fox, B., Maples, P., Hamilton, S., Borellini, F., Lin, A., Morali, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh028 · Cited by 244
Self-citationParekh, V. V., Prasad, D. V. R., Banerjee, P. P., Joshi, B. N., Kumar, A., & Mishra, G. C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.5897 · Cited by 240
Non-small Cell Lung Cancer Cyclooxygenase-2-dependent Invasion Is Mediated by CD44
Dohadwala, M., Luo, J., Zhu, L., Lin, Y., Dougherty, G. J., Sharma, S., Huang, M., Põld, M., Batra, R. K., & Dubinett, S. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100140200 · Cited by 236
Modulation of T-cell function by gliomas
Roszman, T., Elliott, L., & Brooks, W. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90068-5 · Cited by 234
Ahmadzadeh, M., & Rosenberg, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5215 · Cited by 225
Yamaguchi, Y., Tsumura, H., Miwa, M., & Inaba, K. (1997) · STEM CELLS · doi:10.1002/stem.150144 · Cited by 215
Nestle, F. O., Burg, G., Fäh, J., Wrone-Smith, T., & Nickoloff, B. J. (1997) · Europe PMC (PubMed Central) · Cited by 164
Lowest dose interleukin-2 immunotherapy [see comments]
Smith, K. (1993) · Blood · doi:10.1182/blood.v81.6.1414.bloodjournal8161414 · Cited by 161
Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice.
Fontana, A., Frei, K., Bodmer, S., Hofer, E., Schreier, M. H., Palladino, M. A., & Zinkernagel, R. M. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.10.3230 · Cited by 160
Autologous Dendritic Cell Vaccines for Non–Small-Cell Lung Cancer
Hirschowitz, E. A., Foody, T., Kryscio, R., Dickson, L., Sturgill, J., & Yannelli, J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.074 · Cited by 158
Sato, K., Kawasaki, H., Nagayama, H., Enomoto, M., Morimoto, C., Tadokoro, K., Juji, T., & Takahashi, T. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2285 · Cited by 152
Kong, F., Jirtle, R. L., Huang, D. H., Clough, R. W., & Anscher, M. S. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991101)86:9<1712::aid-cncr12>3.0.co;2-v · Cited by 135
Ratto, G. B., Zino, P., Mirabelli, S., Minuti, P., Aquilina, R., Fantino, G., Spessa, E., Ponte, M., Bruzzi, P., & Melioli, G. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960715)78:2<244::aid-cncr9>3.0.co;2-l · Cited by 121
Vaccines in cancer: GVAX®, a GM-CSF gene vaccine
Nemunaitis, J. J. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.3.259 · Cited by 117
Self-citationKasid, A., Bell, G. I., & Director, E. P. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.2.690 · Cited by 116
Raez, L. E., Cassileth, P. A., Schlesselman, J. J., Sridhar, K. S., Padmanabhan, S., Fisher, E., Baldie, P., & Podack, E. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.197 · Cited by 114
Marzo, A. L., Fitzpatrick, D. R., Robinson, B. W. S., & Scott, B. (1997) · UWA Profiles and Research Repository (University of Western Australia) · Cited by 100
Fakhrai, H., Mantil, J., Liu, L., Nicholson, G. L., Murphy-Satter, C. S., Ruppert, J. M., & Shawler, D. L. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700975 · Cited by 99
Self-citationJiang, F., Yin, Z., Caraway, N. P., Li, R., & Katz, R. L. (2004) · Neoplasia · doi:10.1593/neo.04142 · Cited by 92
Weber, F., Byrne, S. N., Le, S., Brown, D. A., Breit, S. N., Scolyer, R. A., & Halliday, G. M. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0652-3 · Cited by 83
Hirte, H. W., & Clark, D. A. (1991) · Cancer Immunology Immunotherapy · doi:10.1007/bf01789047 · Cited by 71
Breaking tolerance in cancer immunotherapy: time to ACT
Overwijk, W. W. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.01.011 · Cited by 68
Lissoni, P., Meregalli, S., Fossati, V., et al. (1994) · Tumori Journal · doi:10.1177/030089169408000611 · Cited by 63
Ruffini, P. A., Rivoltini, L., Silvani, A., Boiardi, A., & Parmiani, G. (1993) · Cancer Immunology Immunotherapy · doi:10.1007/bf01742258 · Cited by 61
Prognostic significance of cytokine modulation in non‐small cell lung cancer
Neuner, A., Schindel, M., Wildenberg, U., Muley, T., Lahm, H., & Fischer, J. R. (2002) · International Journal of Cancer · doi:10.1002/ijc.10604 · Cited by 57
Park, J. A., Wang, E., Kurt, R. A., Schluter, S. F., Hersh, E. M., & Akporiaye, E. T. (1997) · PubMed · Cited by 56
Jakowlew, S. B., Mathias, A., Chung, P., & Moody, T. W. (1995) · PubMed · Cited by 54
The development of immunotherapies for non-small cell lung cancer
Salgaller, M. L. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.3.265 · Cited by 49
NAGANUMA, H., SASAKI, A., SATOH, E., NAGASAKA, M., NAKANO, S., ISOE, S., TASAKA, K., & NUKUI, H. (1996) · Neurologia medico-chirurgica · doi:10.2176/nmc.36.789 · Cited by 42
Antisense TGF-?2 Immunotherapy for Hepatocellular Carcinoma: Treatment in a Rat Tumor Model
Maggard, M. A., Meng, L., Ke, B., Allen, R. B., Devgan, L. L., & Imagawa, D. K. (2001) · Annals of Surgical Oncology · doi:10.1007/s10434-001-0032-6 · Cited by 39
Cytokine secretion: clinical relevance of immunosuppression in non-small cell lung cancer
Neuner, A., Schindel, M., Wildenberg, U., et al. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00350-6 · Cited by 34
Dorigo, O., Shawler, D. L., Royston, I., Sobol, R. E., Berek, J. S., & Fakhrai, H. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.5151 · Cited by 31
Self-citationSmall cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
Yamazaki, K., Spruill, G., Rhoderick, J. B., Spielman, J., Savaraj, N., & Podack, E. R. (1999) · PubMed · Cited by 26
Hirte, H. W., Clark, D. A., O'Connell, G. J., et al. (1992) · Cellular Immunology · doi:10.1016/0008-8749(92)90281-s · Cited by 25
Ratto, G. B., Cafferata, M. A., Scolaro, T., et al. (2000) · Journal of Immunotherapy · doi:10.1097/00002371-200001000-00019 · Cited by 17
Technology evaluation: BLP-25, Biomira Inc.
Morse, M. A. (2001) · PubMed · Cited by 14
Marzo, A., Fitzpatrick, D. R., Scott, B., Bundell, C. S., & Robinson, B. W. S. (1996) · Lung Cancer · doi:10.1016/0169-5002(96)81643-6 · Cited by 8
Downregulation of Transforming Growth Factor β as Therapeutic Approach for Brain Tumors
Fakhrai, H., Gramatikova, S. I., & Safaei, R. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-035-3_14 · Cited by 3
Self-citation
Cited by
Non-small cell lung cancer: current treatment and future advances
Zappa, C., & Mousa, S. A. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.07 · Cited by 1,944
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Metadata
- Authors
- Nemunaitis, J., Dillman, R. O., Schwarzenberger, P. O., Senzer, N., Cunningham, C., Cutler, J., Tong, A., Kumar, P., Pappen, B., Hamilton, C., DeVol, E., Maples, P. B., Liu, L., Chamberlin, T., Shawler, D. L., & Fakhrai, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-10-10
- Volume
- 24
- Issue
- 29
- Pages
- 4721-4730
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2156763707
- Cited by
- 367
- References
- 79
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.